Laurus Labs inks pact with MPP to produce molnupiravir
PTI, Jan 21, 2022, 11:46 AM IST
Image Source: Wikimedia
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir.
”We are happy to sign an agreement to manufacture the oral COVID-19 anti-viral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission,” Laurus Labs Founder and CEO Satyanarayana Chava said in a regulatory filing.
Molnupiravir is an orally administered ribonucleoside analog that inhibits the replication of SARS CoV2, and clinical studies have shown this drug to be active against the most common COVID-19 variants.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Baku climate talks: The ‘X’ factor that could determine future of Global South
Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial
Gautam Adani charged in US with USD 250 mn bribery, fraud
India’s GDP growth likely to slip at 6.5 pc, maintains 7 pc estimate for FY25: Icra
RBI cautions public about ‘deepfake’ video of governor being circulated on social media
MUST WATCH
Latest Additions
SC notice to Gujarat govt on Asaram’s plea seeking suspension of sentence in 2013 rape case
BJP stages protest against Karnataka govt over Waqf properties row
US charges against Adani, 7 others could lead to arrest warrants, extradition bid: attorney
Youth attempts suicide after being humiliated in public for wearing ripped jeans in Belthangady
Baku climate talks: The ‘X’ factor that could determine future of Global South
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.